Vaxart Inc Up 4.55% To $1.15 After Earnings Beat

Vaxart Inc (VXRT) said after close Thursday that it lost $0.12 per share in quarter four 2023.

On the revenue line, the company reported $3.2 million, beating estimates by $2 million.

In the same quarter a year ago, the company lost $0.18 per share on revenue of $22 thousand.

The stock is up 4.55% to $1.15 after the report.

Despite revenues increasing, earnings decreased, signaling a decline in profit margins.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bearish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 73. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.